Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05067140 · ClinicalTrials.gov registry record · Phase 1

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

A Phase 1 study of Prostate Cancer Metastatic, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
152
Enrollment target
20
Study locations

NCT05067140 is a Phase 1 study of Prostate Cancer Metastatic that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 152 participants, below the 219-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05067140, a Phase 1 study of Prostate Cancer Metastatic, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
152 participants
Enrollment target
20
Study locations

Study Summary

A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.

Conditions Studied

Prostate Cancer Metastatic

Interventions

  • DRUG ARV-766 Part A&B
  • DRUG ARV-766 + Abiraterone Part C&D

Study Locations (20)

California

  • Clinical Trial Site - Duarte
  • Clinical Trial Site - Fresno
  • Clinical Trial Site - La Jolla
  • Clinical Trial Site - Orange
  • Clinical Trial Site - Santa Monica

New York

  • Clinical Trial Site - Buffalo
  • Clinical Trial Site - New York

Pennsylvania

  • Clinical Trial Site - Philadelphia
  • Clinical Trial Site - Pittsburgh

Connecticut

  • Clinical Trial Site - New Haven

District of Columbia

  • Clinical Trial Site - Washington D.C.

Florida

  • Clinical Trial Site - Lake Mary

Illinois

  • Clinical Trial Site - Chicago

Louisiana

  • Clinical Trial Site - New Orleans

Trial Details

FieldValue
Enrollment Target 152 participants
Start Date 2021-09-02
Est. Completion 2027-05-25
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05067140

The ClinicalTrials.gov registry entry for NCT05067140 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 17 other Prostate Cancer Metastatic trials with a reported enrollment target (31% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which ARV-766 Part A&B is the first listed.

NCT05067140 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05067140 about?

NCT05067140 is a clinical study titled "A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer". A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.

What is the current status of trial NCT05067140?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2021-09-02. Estimated completion is 2027-05-25.

What conditions does trial NCT05067140 study?

This clinical trial studies the following conditions: Prostate Cancer Metastatic.

What interventions are being tested in trial NCT05067140?

The interventions under investigation include: ARV-766 Part A&B (DRUG), ARV-766 + Abiraterone Part C&D (DRUG).

Who is sponsoring clinical trial NCT05067140?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05067140 being conducted?

This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer Metastatic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer Metastatic

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.